Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $51.40 Average Price Target from Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average rating of “Buy” from the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $51.40.

Several brokerages have recently commented on DYN. Stifel Nicolaus increased their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Morgan Stanley lifted their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th.

Dyne Therapeutics Price Performance

Shares of Dyne Therapeutics stock opened at $35.24 on Wednesday. The company has a 50 day simple moving average of $37.55 and a two-hundred day simple moving average of $34.53. The firm has a market cap of $3.08 billion, a PE ratio of -8.88 and a beta of 1.05. Dyne Therapeutics has a 1 year low of $6.40 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, research analysts anticipate that Dyne Therapeutics will post -2.96 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other news, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO John Cox acquired 32,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was acquired at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at approximately $264,320. This represents a -100.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dirk Kersten sold 23,671 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $35.35, for a total value of $836,769.85. Following the sale, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 158,975 shares of company stock worth $5,693,789. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in Dyne Therapeutics by 4.3% in the second quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after purchasing an additional 352 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Amalgamated Bank increased its stake in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after acquiring an additional 796 shares in the last quarter. Principal Financial Group Inc. lifted its position in Dyne Therapeutics by 5.9% during the 1st quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after acquiring an additional 857 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.